MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of the Rheumatic Diseases
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,612 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,612 works in the cohort · of 4,299,418page 16 of 53

Labels cover 7 of 2,612 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,612 of 2,612 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

aboutno affunlabeled
OP0079 Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 12 Months After YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE
Eric F. Morand, Rangi Kandane‐Rathnayake, J. Cortés-Hernández, Z. Amoura, Julia Weinmann‐Menke, B. A. Maurer +18 more
2025· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
afffundno abstractunlabeled
POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
Laura C. Coates, R. B. M. Landewé, Iain B. McInnes, Philip J. Mease, Christopher T. Ritchlin, Y. Tanaka +10 more
2023· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
fundno affno abstractunlabeled
Pharmacogenetics in the rheumatic diseases
Bruce N. Cronstein
2004· review· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affno abstractgemma · metaresearch+metaepi_broadgpt · metaresearch+metaepi_narrow+metaepi_broadmodels split
Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group
Sabrina Mai Nielsen, Helene Storgaard, Torkell Ellingsen, Beverley Shea, George A. Wells, Vivian Welch +12 more
2020· review· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · metaresearch+metaepi_broadconsensus · none
6
citations
affno abstractunlabeled
Anti-Ku antibodies: important points to consider
Michael Mähler, Minoru Satoh, Marvin J. Fritzler
2019· letter· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About